Nasdaq · CIK 0001129928
ONCY ONCOLYTICS BIOTECH INC
Insider trading from SEC Form 4. Last filing Jun 3, 2026. Close $0.56 on Oct 9, 2026, +4% from the 52-week low and -56% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
ONCYOct 9, 2026 · close 0.56
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ONCOLYTICS BIOTECH INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Jared Kelly Chief Executive Officer buy | $4,848 5,050 shares | +5% | - | |
| 29Weak | James T. Parsons director buy | $10k 10,000 shares | +31% | - | |
| 45Moderate | Patricia S Andrews director buy | $30k 35,400 shares | +83% | - | |
| 45Moderate | Andrew Aromando Chief Business Officer buy | $25k 29,600 shares | +116% | - | |
| 36Weak | Deborah Margaret Brown director buy | $21k 25,000 shares | +29% | - | |
| 33Weak | Allison Hagerman VP, Product Development buy | $8,298 10,000 shares | +10% | - | |
| 30Weak | Thomas Charles Heineman Chief Medical Officer buy | $10k 12,132 shares | +4% | - | |
| 51Moderate | Jared Kelly Chief Executive Officer buy | $30k 35,100 shares | +47% | - | |
| 37Weak | Kirk Look Chief Financial Officer buy | $10k 12,000 shares | +4% | - | |
| 38Weak | Wayne Pisano director buy | $25k 30,000 shares | +6% | - | |
| 50Moderate | Bernd R. Seizinger director buy | $83k 100,000 shares | +21% | - | |
| 31Weak | Bernd R. Seizinger director buy | $104k 100,000 shares | +27% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Patricia S Andrews director | AGrant or award Stock Optionderivative | +30,000 | $0.00 | $0 | 30,000 | Jun 3, 2026 |
| Jun 1, 2026 | Andrew Aromando Chief Business Officer | AGrant or award Stock Optionderivative | +260,000 | $0.00 | $0 | 260,000 | Jun 3, 2026 |
| Mar 12, 2026 | Jared Kelly Chief Executive Officer | POpen-market purchase Common Shares | +5,050 | $0.96 | $4,848 | 114,050 | Mar 13, 2026 |
| Mar 11, 2026 | James T. Parsons director | POpen-market purchase Common Shares | +10,000 | $1.03 | $10k | 41,849 | Mar 13, 2026 |
| Feb 12, 2026 | Patricia S Andrews director | POpen-market purchase Common Shares | +35,400 | $0.86 | $30k | 78,128 | Feb 13, 2026 |
| Feb 12, 2026 | Deborah Margaret Brown director | POpen-market purchase Common Shares | +25,000 | $0.85 | $21k | 109,851 | Feb 13, 2026 |
| Feb 12, 2026 | Allison Hagerman VP, Product Development | POpen-market purchase Common Shares | +10,000 | $0.83 | $8,298 | 115,059 | Feb 13, 2026 |
| Feb 12, 2026 | Thomas Charles Heineman Chief Medical Officer | POpen-market purchase Common Shares | +12,132 | $0.83 | $10k | 282,818 | Feb 13, 2026 |
| Feb 12, 2026 | Kirk Look Chief Financial Officer | POpen-market purchase Common Shares | +12,000 | $0.84 | $10k | 287,515 | Feb 13, 2026 |
| Feb 12, 2026 | Wayne Pisano director | POpen-market purchase Common Shares | +30,000 | $0.84 | $25k | 492,414 | Feb 13, 2026 |
| Feb 11, 2026 | Andrew Aromando Chief Business Officer | POpen-market purchase Common Shares | +29,600 | $0.86 | $25k | 55,100 | Feb 13, 2026 |
| Feb 11, 2026 | Jared Kelly Chief Executive Officer | POpen-market purchase Common Shares | +5,600 | $0.84 | $4,682 | 79,500 | Feb 13, 2026 |
| Feb 11, 2026 | Bernd R. Seizinger director | POpen-market purchase Common Shares | +60,000 | $0.83 | $50k | 526,991 | Feb 13, 2026 |
| Feb 12, 2026 | Jared Kelly Chief Executive Officer | POpen-market purchase Common Shares | +29,500 | $0.84 | $25k | 109,000 | Feb 13, 2026 |
| Feb 12, 2026 | Bernd R. Seizinger director | POpen-market purchase Common Shares | +40,000 | $0.85 | $34k | 566,991 | Feb 13, 2026 |
| Jan 16, 2026 | Bernd R. Seizinger director | POpen-market purchase Common Shares | +100,000 | $1.04 | $104k | 466,991 | Jan 20, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Patricia S Andrewsdirector
- Andrew AromandoChief Business Officer
- Deborah Margaret Browndirector
- Allison HagermanVP, Product Development
- Thomas Charles HeinemanChief Medical Officer
- Jared KellyChief Executive Officer
- Kirk LookChief Financial Officer
- James T. Parsonsdirector
- Wayne Pisanodirector
- Bernd R. Seizingerdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.